SCHEMBL20964683

SCHEMBL20964683

Cc1cc(CSc2ccccc2C(=O)N2CCN(c3cccc(C)c3C)CC2)on1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.53
L3MBTL1 Q9Y468 3/20 0.53
KDM4E B2RXH2 1/20 0.53
GLA P06280 1/20 0.53
GAA P10253 1/20 0.53
TSHR P16473 4/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
ALDH1A1 P00352 3/20 0.52
MAPT P10636 5/20 0.50
NPC1 O15118 3/20 0.50
POLB P06746 1/20 0.48
HTT P42858 2/20 0.48
MAPK1 P28482 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
AR P10275 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
STAT3 P40763 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20964636 0.90 SMN1; SMN2 (0.53) LMNAL3MBTL1GAATSHRSMN1; SMN2
SCHEMBL20964553 0.86 ALDH1A1 (0.69) LMNATSHRSMN1; SMN2ALDH1A1MAPT
SCHEMBL20964637 0.85 LMNA (0.60) LMNAL3MBTL1KDM4ETSHRSMN1; SMN2
SCHEMBL20964665 0.84 LMNA (0.62) LMNATSHRSMN1; SMN2ALDH1A1MAPT
SCHEMBL20965377 0.84 LMNA (0.58) LMNAL3MBTL1TSHRSMN1; SMN2ALDH1A1
SCHEMBL20964733 0.84 SMN1; SMN2 (0.75) LMNAL3MBTL1KDM4EGLAGAA
SCHEMBL20964599 0.83 LMNA (0.59) LMNATSHRSMN1; SMN2ALDH1A1MAPT
SCHEMBL20964548 0.83 ALDH1A1 (0.59) LMNAKDM4EGAATSHRSMN1; SMN2
SCHEMBL20964655 0.82 LMNA (0.52) LMNATSHRSMN1; SMN2ALDH1A1HTT
SCHEMBL20964705 0.80 ALDH1A1 (0.49) LMNAKDM4ETSHRSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-12-01 US disclosed
US-20190127361-A1 Therapeutic Compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127361-A1 Therapeutic Compounds SDHA, SLC10A1, SERPINC1 LMNA 1413/4885L3MBTL1 4755/4885KDM4E 4616/4885
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents SERPINC1, F12, RPL35 LMNA 897/4885L3MBTL1 4517/4885KDM4E 2648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.